CCL2 and neoplasm: In addition, blockade of β-ARs signaling (PROP + SR, blocking all β-ARs) dramatically abrogated the EE-induced CCL2 reduction in the blood (Fig. 5D) and tumor tissue (Fig. 5B, E, F) in DEN + CCl4-induced HCC model.